- Bombshell development in the wearables market as Nike bows out (well, of the hardware side, anyway), putting the brakes on future Fuelband iterations amid speculation that they're clearing the way for a collaboration with Apple.
- A trio large pharmas traded units amid continued emphasis on narrowly focused portfolios. Novartis bought a pair of GSK cancer drugs to complement its Gleevec franchise, and in turn sold its vaccines business to GSK while also selling its animal health division to Lilly.
- For all the payer gnashing of teeth over Gilead's pricey hep C drug Sovaldi, so far, it's not crimping sales. The brand crushed analysts expectations for $1.13 billion in sales by more than a billion. However, several medical societies are starting to factor costs into treatment guidelines or are threatening to, anyway.
- There's now a whole medical scribe staffing industry to help physicians feed their EHRs in patient consults.
- Is Facebook dipping a toe in the fitness tracking market with its latest purchase.
- The comments period for FDA's first draft guidance on social media closed, and Klick Health has an overview of the comments. The sore spots are the definitions of editorial control and influence.
- Nine out of ten Americans are willing to share their health data with researchers, but for most, it's conditional, and data privacy is a concern.
- Apple is embracing digital advertising in a big way for the first time after pursuing a TV-centric advertising strategy for its entire existence. Wait, what> Who says pharma's an old fuddy-duddy of an industry, anyway
- - See more at: http://healthandpharmainsight.tumblr.com/post/83842375761/in-case-you-missed-it#sthash.AjKFLjGO.dpuf
By Matthew Arnold, Principal Analyst
This look into Merck's Practice Fusion partnership is exciting news for all of us who've been wondering what pharma engagement of physicians and patients through electronic health records (EHRs) might look like. Merck is giving users of Practice Fusion's EHR a dashboard through which they can identify patients who are behind on their vaccinations and notify them that it's time to get their shots, Forbes reports:
"Alerting doctors or patients for an overdue vaccination or test has long been the job of payers. Merck's intervention through an electronic health record is a first for a pharmaceutical company as it harnesses newly emergent technology and data to get closer to patients."
Practice Fusion says the program can also alert providers that a patient needs a vaccine during the patient visit:
Practice Fusion's 112,000 monthly active medical professionals now have a real-time dashboard that compares each provider's patient population to those of other Practice Fusion providers, allowing them to actively track the percentage of their adult patients that have received select vaccinations based on guidelines from the Centers for Disease Control and Prevention (CDC). This gives them a quantified view of their vaccination rates. During patient office visits, the program notifies providers within the EHR if a vaccine is recommended for that particular patient based on guidelines from the CDC.
While Practice Fusion's EHR is ad-supported, Merck won't plug products through the program, writes Zina Moukheiber in Forbes. However, the company does stand to benefit from a halo effect by association not to mention the resulting lift in prescriptions for vaccinations. It's exactly the sort of win-win-win scenario envisioned by proponents of pharma-EHR collaboration, who have said that if pharmas are to penetrate this fourth screen, they will have to offer all parties something of value, because the old promotional paradigm is obsolete here. With physicians now spending more hours per day in their EHRs than they are on all other digital resources, it's an essential challenge for the industry.